My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Cassava Sciences, Inc. - Common Stock (NQ:SAVA)

2.170 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Feb 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Cassava Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

Unpacking the Latest Options Trading Trends in Cassava Sciences ↗

November 26, 2024

Via Benzinga

This Goldman Sachs Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

November 26, 2024

Via Benzinga

Cassava Sciences, Zoom, Kohl's, Rivian, Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗

November 25, 2024

SAVA, ZM, KSS, RIVN, TSLA were among the trending stocks among investors on Monday Nov. 25, 2024.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 25, 2024

Via Benzinga

Gold Down Over 3%; Rigetti Computing Shares Spike Higher ↗

November 25, 2024

Via Benzinga

Unpacking the Latest Options Trading Trends in Cassava Sciences ↗

November 05, 2024

Via Benzinga

How Is The Market Feeling About Cassava Sciences? ↗

October 25, 2024

Via Benzinga

$1000 Invested In This Stock 5 Years Ago Would Be Worth $20,000 Today ↗

October 09, 2024

Via Benzinga

Cassava Sciences Unusual Options Activity ↗

September 27, 2024

Via Benzinga

Crude Oil Down 3%; Chicago Fed National Activity Index Falls In October ↗

November 25, 2024

Via Benzinga

Topics Economy

'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update ↗

November 25, 2024

Pharma bro Martin Shkreli predicted Cassava Sciences stock would fall and the company would miss primary endpoints for its Phase 3 trial.

Via Benzinga

Dow Surges Over 300 Points; Bath & Body Works Posts Upbeat Earnings ↗

November 25, 2024

Via Benzinga

Topics Stocks

Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies ↗

November 25, 2024

Cassava Sciences' stock fell after Phase 3 simufilam trial failed to meet key endpoints, prompting the discontinuation of its Alzheimer's studies.

Via Benzinga

Cassava Sciences Plummets 85% After Embattled Alzheimer's Drug Flops ↗

November 25, 2024

The company tested simufilam in patients with mild-to-moderate Alzheimer's disease.

Via Investor's Business Daily

Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

November 25, 2024

Via Benzinga

Friday's Top 5 Trending Stocks: What's The Scoop On GameStop, SoFi, Tesla? ↗

November 08, 2024

GameStop, SoFi, Tesla, Cassava Sciences and Anavex Life Sciences are the top five trending stocks on Stocktwits Friday. Here's a look at what's going on:

Via Benzinga

Analysts Believe Cassava Sciences Now Has 300% Upside From Here

October 30, 2024

Cassava Sciences faces controversy over its Alzheimer's drug, simufilam, amid fraud allegations, yet analysts maintain a Buy rating with high upside potential.

Via MarketBeat

Topics Fraud Lawsuit

10 Health Care Stocks With Whale Alerts In Today's Session ↗

October 16, 2024

Via Benzinga

Crude Oil Falls Over 4%; US Trade Deficit Narrows In August ↗

October 08, 2024

Via Benzinga

What's Going On With Alzheimer's-Focused Cassava Sciences On Tuesday? ↗

October 08, 2024

Cassava Sciences Inc. has agreed to a $40 million settlement over SEC charges related to misleading data for simufilam. The firm anticipates top-line results from the ReTHINK Phase 3 trial before...

Via Benzinga

Topics Regulatory Compliance

PepsiCo, DocuSign, Robinhood And Other Big Stocks Moving Higher On Tuesday ↗

October 08, 2024

Via Benzinga

This Wells Fargo Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

October 08, 2024

Via Benzinga

Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer ↗

October 08, 2024

Bio-Path is advancing its obesity treatment BP1001-A and completing trials for BP1002 in acute myeloid leukemia, targeting resistance mechanisms in treatment. Preclinical studies for obesity are set...

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

October 07, 2024

Via Benzinga

Why Cassava Sciences Stock Dived by Almost 11% Today ↗

September 27, 2024

Without admitting wrongdoing, the company put a regulatory controversy to rest, but this was expensive.

Via The Motley Fool

Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

September 27, 2024

Via Benzinga

SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty ↗

September 27, 2024

Cassava Sciences and its executives face a $40 million SEC settlement over manipulated data in an Alzheimer's drug trial, misleading investors with false claims of cognitive improvement and selective...

Via Benzinga

Topics Regulatory Compliance

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

September 27, 2024

Via Benzinga

Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket ↗

September 27, 2024

Via Benzinga

Cassava Sciences Stock Rises On Interim Safety Review Of Simufilam Phase 3 Trials ↗

September 24, 2024

Cassava Sciences, Inc. (NASDAQ: SAVA) shares trading higher following the announcement of a positive interim safety review of its Alzheimer's drug candidate, simufilam. Here's what you need to know.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.